We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+32.97%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$340M
AUM Growth
+$36.5M
Cap. Flow
-$17.9M
Cap. Flow %
-5.28%
Top 10 Hldgs %
87.03%
Holding
26
New
1
Increased
2
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$5.69M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$2.77M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$966K

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$12.3M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$8.19M
3
RGNX icon
Regenxbio
RGNX
+$6.53M
4
OCRX
Ocera Therapeutics, Inc.
OCRX
+$322K
5
ZSAN
Zosano Pharma Corporation
ZSAN
+$77K

Sector Composition

Rank Sector Weight
1 Healthcare 93.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$744M
$85.2M 25.08%
2,858,569
-425,000
-13% -$12.3M
ASND icon
2
Ascendis Pharma A/S
ASND
$16.7B
$49.5M 14.55%
1,766,832
– –
NBRV
3
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$48.3M 14.2%
16,086
– –
CDXS icon
4
Codexis
CDXS
$136M
$25.4M 7.48%
5,294,825
– –
EIGR
5
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$20.5M 6.02%
59,570
– –
AAAP
6
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$19.3M 5.67%
483,786
+27,988
+6% +$966K
AIMT
7
DELISTED
Aimmune Therapeutics
AIMT
$16.6M 4.88%
763,009
– –
SBBP
8
DELISTED
Strongbridge Biopharma plc.
SBBP
$14.3M 4.19%
3,000,000
– –
SLNO
9
DELISTED
Soleno Therapeutics
SLNO
$10.4M 3.07%
195,937
+96,511
+97% +$5.69M
TMBR
10
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$6.47M 1.9%
854
– –
TRVN
11
DELISTED
Trevena, Inc.
TRVN
$6.34M 1.87%
2,765
– –
AKTX
12
Akari Therapeutics
AKTX
$14.8M
$5.84M 1.72%
660
– –
AGRX
13
DELISTED
Agile Therapeutics
AGRX
$4.85M 1.43%
757
– –
AUPH icon
14
Aurinia Pharmaceuticals
AUPH
$1.92B
$4.4M 1.3%
+600,000
New +$2.77M
FOMX
15
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.23M 1.24%
855,000
– –
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.73M 1.1%
60,957
– –
CRSP icon
17
CRISPR Therapeutics
CRSP
$4.68B
$3.24M 0.95%
148,878
– –
RGNX icon
18
Regenxbio
RGNX
$615M
$3.17M 0.93%
164,403
-338,460
-67% -$6.53M
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
$2.35M 0.69%
300,325
– –
DVAX
20
DELISTED
Dynavax Technologies
DVAX
$2.14M 0.63%
359,828
– –
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.05M 0.6%
14,286
– –
RVNC
22
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.61M 0.47%
77,373
– –
CAPNW
23
DELISTED
Capnia, Inc. Series A Warrant
CAPNW
$113K 0.03%
943,858
– –
ZSAN
24
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-141
Closed -$77K
OCRX
25
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-153,331
Closed -$322K
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Vivo Capital held 26 positions worth $340M, up 12% from $303M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Vivo Capital withdrew a net $17.9M in Q1 2017, closing 3 positions and reducing 2 holdings. Its most notable exit was CoLucid Pharmaceuticals, Inc., an estimated $8.19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier.

Against the trend, Vivo Capital opened a new position in Aurinia Pharmaceuticals worth $4.4M.

  • Vivo Capital's largest Q1 2017 buy was Aurinia Pharmaceuticals: 600,000 shares worth $4.4M.
  • Vivo Capital added most to Soleno Therapeutics in Q1 2017, an estimated $5.69M increase.
  • Vivo Capital's biggest Q1 2017 reduction was Aclaris Therapeutics, cutting an estimated $12.3M.
  • Vivo Capital fully exited CoLucid Pharmaceuticals, Inc. in Q1 2017, selling an estimated $8.19M.
  • Vivo Capital's ten largest holdings make up 87% of its $340M portfolio in Q1 2017.
  • Vivo Capital opened 1 new position and closed 3 in Q1 2017.
  • Vivo Capital's portfolio value rose 12% quarter-over-quarter to $340M.

Based on Vivo Capital's 13F filing for Q1 2017, filed 15 May 2017.